Catalyst Pharmaceuticals, Inc. $CPRX Shares Acquired by Future Fund LLC

Future Fund LLC lifted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 26.3% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 94,727 shares of the biopharmaceutical company’s stock after buying an additional 19,754 shares during the quarter. Future Fund LLC owned approximately 0.08% of Catalyst Pharmaceuticals worth $2,345,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Deerfield Management Company L.P. lifted its holdings in Catalyst Pharmaceuticals by 72.8% in the third quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock valued at $98,003,000 after acquiring an additional 2,095,291 shares during the period. Janus Henderson Group PLC grew its stake in shares of Catalyst Pharmaceuticals by 200.6% during the 4th quarter. Janus Henderson Group PLC now owns 1,719,767 shares of the biopharmaceutical company’s stock worth $40,124,000 after purchasing an additional 1,147,565 shares during the period. Morgan Stanley grew its stake in shares of Catalyst Pharmaceuticals by 59.1% during the 4th quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock worth $68,466,000 after purchasing an additional 1,089,775 shares during the period. Glenmede Investment Management LP grew its stake in shares of Catalyst Pharmaceuticals by 781.8% during the 3rd quarter. Glenmede Investment Management LP now owns 680,224 shares of the biopharmaceutical company’s stock worth $13,400,000 after purchasing an additional 603,084 shares during the period. Finally, Bank of America Corp DE increased its holdings in shares of Catalyst Pharmaceuticals by 30.6% during the 2nd quarter. Bank of America Corp DE now owns 2,365,675 shares of the biopharmaceutical company’s stock valued at $51,335,000 after purchasing an additional 554,200 shares in the last quarter. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock opened at $31.49 on Friday. The company has a market cap of $3.86 billion, a price-to-earnings ratio of 18.10, a PEG ratio of 0.96 and a beta of 0.74. The stock has a 50 day simple moving average of $31.35 and a 200-day simple moving average of $27.01. Catalyst Pharmaceuticals, Inc. has a 1-year low of $19.05 and a 1-year high of $32.56.

Analyst Ratings Changes

A number of brokerages recently issued reports on CPRX. Weiss Ratings raised shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, June 3rd. HC Wainwright cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $35.00 to $31.50 in a report on Thursday, May 28th. Oppenheimer cut shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Truist Financial upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Wall Street Zen lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).